Core - Chemistry

Griffin, John

Abstract

Core B is designed to provide synthetic materials for use in Projects 1 and 2. The Core leader's experience with design , synthesis, and study of amino acid derivatives, peptides, and modified peptides will facilitate the translation of hypotheses into new reagents and experimental strategies.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Research Program Projects (P01)
• Project #: 5P01AI041520-04
• Application #: 6336258
• Project Start: 2000-08-01
• Project End: 2001-07-31
• Budget Start: 1997-10-01
• Budget End: 1998-09-30
• Support Year: 4
• Fiscal Year: 2000
• Total Cost: $185,062

Institution

• Name: Stanford University
• DUNS #: 009214214
• City: Stanford
• State: CA
• Country: United States
• Zip Code: 94305

Publications

Shachaf, Catherine M; Perez, Omar D; Youssef, Sawsan et al. (2007) Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 110:2674-84

Andersen, Carsten B; Sakaue, Hiroshi; Nedachi, Taku et al. (2003) Protein kinase B/Akt is essential for the insulin- but not progesterone-stimulated resumption of meiosis in Xenopus oocytes. Biochem J 369:227-38

Ling, X; Tamaki, T; Xiao, Y et al. (2000) An immunosuppressive and anti-inflammatory HLA class I-derived peptide binds vascular cell adhesion molecule-1. Transplantation 70:662-7

Boytim, M L; Lilly, P; Drouvalakis, K et al. (2000) A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling. J Clin Invest 105:1447-53

Murphy, B; Krensky, A M (1999) HLA-derived peptides as novel immunomodulatory therapeutics. J Am Soc Nephrol 10:1346-55

Boytim, M L; Lyu, S C; Jung, R et al. (1998) Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65-79 of an HLA class II sequence: functional similarities but mechanistic differences with the immunosuppressive drug rapamycin. J Immunol 160:2215-22